The strong Q2 beat on revenue and profitability confirms YUTREPIA's commercial momentum, but the stock's next major catalyst is the resolution of the United Therapeutics patent litigation, which could block sales. Monitor for court rulings on injunctive relief and upcoming Phase 3 Re-Spire enrollment updates for L606.
Price Chart
Executive Summary
Liquidia reported Q2 2026 net product sales of $170.4M (+31% QoQ), net income of $74.7M ($0.74 diluted EPS), and adjusted EBITDA of $96.3M. While EPS of $0.74 missed consensus estimates of $0.84, the company delivered its fourth consecutive quarter of increasing profitability with strong cash generation ($284.2M ending cash, up $61.4M QoQ). The ongoing patent litigation with United Therapeutics seeking injunctive relief remains a key overhang on the stock.
Key Financial Metrics
Key Facts
- YUTREPIA net product sales of $170.4M in Q2 2026, up 31% from Q1 2026
- Net income of $74.7M, fourth consecutive quarter of increasing profitability
- Adjusted EBITDA of $96.3M in Q2 2026
- Cash and cash equivalents of $284.2M as of June 30, 2026, up $61.4M from Q1 2026
- Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated since launch
- Progressing 10 clinical studies supporting YUTREPIA and L606
- Ongoing patent litigation with United Therapeutics seeking injunctive relief that could block YUTREPIA sales
Financial Impact
Q2 2026 net product sales of $170.4M; net income of $74.7M; adjusted EBITDA of $96.3M
Risk Factors
- Ongoing patent litigation with United Therapeutics seeking injunctive relief that could block YUTREPIA sales for PAH and/or PH-ILD
- Dependence on single product YUTREPIA for revenue
- Increasing SG&A expenses (+48% YoY) as commercialization scales
- R&D expenses rising 185% YoY driven by L606 program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094411 |
| Document: tm2622888d1_8k.htm | 0001104659-26-094411 |
| Document: tm2622888d1_ex99-2.htm | 0001104659-26-094411 |
| Document: 0001104659-26-094411-index-headers.html | 0001104659-26-094411 |
| Document: 0001104659-26-094411-index.html | 0001104659-26-094411 |
| Document: 0001104659-26-094411.txt | 0001104659-26-094411 |
| 8-K Data (Synthetic) | 0001104659-26-094411 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 8-K | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $42.65 (+25.66%) |
Oct 13, 2026 13d ago | Insider Cluster | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $42.65 (+25.66%) |
Sep 30, 2026 26d ago | 8-K | $27.99 $28.64 | ▼ −2.32% | ▼ −1.58% | $42.65 (−52.38%) |
Sep 3, 2026 7w ago | 8-K | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $42.65 (−37.86%) |
Sep 3, 2026 7w ago | Press Release | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $42.65 (−37.86%) |
Aug 25, 2026 8w ago | Insider Cluster | $71.36 $69.94 | ▼ −1.99% | ▼ −2.65% | $42.65 (−40.23%) |
Aug 21, 2026 9w ago | Insider Cluster | $70.27 $70.49 | ▲ +0.31% | ▼ −0.01% | $42.65 (−39.31%) |
Aug 12, 2026 10w ago | 8-K | $78.79 $72.10 | ▼ −8.49% | ▼ −9.19% | $42.65 (−45.87%) |
Aug 12, 2026 10w ago | Press Release | $78.79 $72.10 | ▲ +8.49% | ▲ +9.19% | $42.65 (+45.87%) |
Jul 29, 2026 12w ago | Insider Cluster | $86.80 $84.11 | ▼ −3.10% | ▼ −3.82% | $42.65 (−50.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers